Erectile Function Following Surgery for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials.

Benign prostatic hyperplasia Benign prostatic obstruction Ejaculation Ejaculatory dysfunction Erectile dysfunction Erectile function International Index of Erectile Function-5 Network meta-analysis Prostatic urethral lift Sexual function

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
08 2021
Historique:
received: 04 07 2020
accepted: 12 04 2021
pubmed: 16 6 2021
medline: 23 2 2022
entrez: 15 6 2021
Statut: ppublish

Résumé

Benign prostatic obstruction (BPO) is associated with sexual dysfunction. Furthermore, numerous BPO interventions may themselves impact sexual function. To perform a systematic review with network meta-analysis to evaluate how BPO interventions affect erectile function. Three databases were searched for randomised controlled trials (RCTs) comparing surgical interventions for BPO. The primary outcome was postoperative International Index of Erectile Function-5 (IIEF-5) score at ten time points up to 72 mo. A random-effects Bayesian network meta-analysis with meta-regression was performed. In comparison to monopolar transurethral resection (mTURP), the mean difference (MD) with 95% credible interval (CrI) and rank probability (rank p) were calculated for interventions. The mean baseline score was studied in meta-regression. τ A total of 48 papers (33 RCTs, 5159 patients, 16 interventions) were included. Prostatic urethral lift (PUL) ranked highest at 1 mo (MD 3.88, 95% CrI -0.47 to 8.25; rank p = 0.742), 6 mo (MD 2.43, 95% CrI -0.72 to 5.62; rank p = 0.581), 12 mo (MD 2.94, 95% CrI -0.26 to 6.12, rank p = 0.782), and 24 mo (MD 3.63, 95% CrI 0.14 to 7.11; rank p = 0.948), at which point statistical significance was reached. At time points up to 60 mo, there were no statistically significant comparisons for other interventions. Analyses were not possible at 18, 48, or 72 mo. β did not reach statistical significance in meta-regression. τ PUL ranked highly and resulted in erectile function improvement at 24 mo compared to mTURP, but direct evidence is lacking. We did not observe significant differences in erectile function following other interventions up to 60 mo. Owing to heterogeneity, our conclusions are weakest at 1 and 60 mo. Further RCTs comparing sexual function outcomes are recommended, such as PUL versus holmium laser or bipolar enucleation. Different surgical treatments can be used to treat benign enlargement of the prostate causing urinary problems. We compared the effects of various treatments on erectile function at time points up to 5 years after surgery. Compared to surgical removal of some of the prostate gland (transurethral resection of the prostate, TURP), a technique called prostatic urethral lift resulted in better erectile function scores at 24 months. However, other treatments did not differ in their effect on erectile function.

Identifiants

pubmed: 34127315
pii: S0302-2838(21)00252-9
doi: 10.1016/j.eururo.2021.04.012
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

174-187

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Alexander Light (A)

Department of Surgery, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Dost Jabarkhyl (D)

Faculty of Life Sciences and Medicine, King's College London, London, UK.

Peter Gilling (P)

Department of Urology, Tauranga Hospital, Bay of Plenty District Health Board, Tauranga, New Zealand.

Gincy George (G)

Translational Oncology & Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Mieke Van Hemelrijck (M)

Translational Oncology & Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Ben Challacombe (B)

Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Sachin Malde (S)

Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Rick Popert (R)

Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Prokar Dasgupta (P)

Faculty of Life Sciences and Medicine, King's College London, London, UK; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: prokar.dasgupta@kcl.ac.uk.

Oussama Elhage (O)

Faculty of Life Sciences and Medicine, King's College London, London, UK; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH